Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI

Nearly half of hospitalized patients with coronavirus disease 2019 (COVID-19) develop AKI, with 20% requiring dialysis. High levels of soluble urokinase plasminogen activator receptor (suPAR)—an immune mediator of kidney injury—predispose patients to AKI in various clinical scenarios, including critical illness. High suPAR levels modulate mitochondrial respiration and induce the generation of…

Read the full article here

Related Articles